Patients with metastatic prostate cancer may benefit from biologic medication-device combination immunotherapy.

Published Date: 10 Apr 2024

Patients with metastatic castrate-resistant tumors showed multiple clinical responses to SYNC-T, an experimental treatment that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Study reveals increase in late-stage breast cancer diagnoses in US

5.

Prostate cancer Q&A: Improving detection and reducing overtreatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot